Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 1/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.50 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.50 |
| ▸ | EPHX2 | P34913 | 10/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.41 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.41 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | CHRNB3 | Q05901 | 1/20 | 0.41 |
| ▸ | CHRNA6 | Q15825 | 1/20 | 0.41 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.41 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.40 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.40 |
| ▸ | BLM | P54132 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19703906 | 0.89 | HSD11B1 (0.45) | HSD11B1CYP2D6KCNH2HRH3EPHX2 | |
| SCHEMBL4550228 | 0.86 | EPHX2 (0.47) | HSD11B1EPHX2ALDH1A1CHRNB2CHRNA3 | |
| SCHEMBL12384632 | 0.84 | CYP2D6 (0.50) | HSD11B1CYP2D6KCNH2HRH3EPHX2 | |
| SCHEMBL12510683 | 0.82 | EPHX2 (0.47) | EPHX2ALDH1A1CHRNB2CHRNA3CHRNA4 | |
| SCHEMBL16591619 | 0.82 | CYP2D6 (0.49) | HSD11B1CYP2D6KCNH2HRH3EPHX2 | |
| SCHEMBL24550414 | 0.82 | ALDH1A1 (0.63) | HSD11B1CYP2D6KCNH2HRH3EPHX2 | |
| SCHEMBL12890994 | 0.82 | CYP2D6 (0.49) | HSD11B1CYP2D6KCNH2HRH3EPHX2 | |
| SCHEMBL20939041 | 0.82 | GNAI3 (0.55) | HSD11B1CYP2D6KCNH2HRH3NPC1 | |
| SCHEMBL12384399 | 0.81 | CYP2D6 (0.47) | HSD11B1CYP2D6KCNH2HRH3EPHX2 | |
| SCHEMBL13964621 | 0.80 | GNAI3 (0.62) | CYP2D6KCNH2HRH3NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230131535-A1 | ARYLMETHYLENE AROMATIC COMPOUNDS AS Kv1.3 POTASSIUM SHAKER CHANNEL BLOCKERS | D. E. SHAW RESEARCH, LLC | 2023-04-27 | — | — | US | disclosed |
| US-20230120619-A1 | BIFUNCTIONAL DEGRADERS OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASES AND THERAPEUTIC USE THEREOF | GILEAD SCIENCES, INC. | 2023-04-20 | — | — | US | disclosed |
| US-20220177508-A1 | C10-Cyclic Substituted 13-Membered Macrolides and Uses Thereof | ZIKANI THERAPEUTICS, INC. | 2022-06-09 | — | — | US | disclosed |
| US-20210002265-A1 | PYRAZOLE DERIVATIVES AS INHIBITORS OF THE WNT SIGNALLING PATHWAY | Université de Lausanne (CH) | 2021-01-07 | — | — | US | disclosed |
| US-20180222882-A1 | PYRIDAZINE DERIVATIVES AS RORc MODULATORS | GENENTECH, INC. (US) | 2018-08-09 | — | — | US | disclosed |
| US-20150353495-A1 | NICOTINAMIDES AS JAK KINASE MODULATORS | ALEXION PHARMACEUTICALS, INC. | 2015-12-10 | — | — | US | disclosed |
| US-9102625-B2 | Nicotinamides as JAK kinase modulators | PORTOLA PHARMACEUTICALS, INC. (US) | 2015-08-11 | — | — | US | disclosed |
| US-20120108566-A1 | NICOTINAMIDES AS JAK KINASE MODULATORS | PORTOLA PHARMACEUTICALS, INC. (US) | 2012-05-03 | — | — | US | disclosed |
| US-20120108566-A1 | NICOTINAMIDES AS JAK KINASE MODULATORS | PORTOLA PHARMACEUTICALS, INC. (US) | 2012-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210002265-A1 | PYRAZOLE DERIVATIVES AS INHIBITORS OF THE WNT SIGNALLING PATHWAY | WNT1, WNT3A, WNT3 | HSD11B1 77/4885CYP2D6 73/4885KCNH2 4233/4885 |
| US-20180222882-A1 | PYRIDAZINE DERIVATIVES AS RORc MODULATORS | RORC, RORB, RORA | HSD11B1 856/4885CYP2D6 623/4885KCNH2 2161/4885 |
| US-20230120619-A1 | BIFUNCTIONAL DEGRADERS OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASES AND THERAPEUTIC USE THEREOF | IRAK1, IRAK2, IRAK4 | HSD11B1 3321/4885CYP2D6 4363/4885KCNH2 4830/4885 |
| US-20220177508-A1 | C10-Cyclic Substituted 13-Membered Macrolides and Uses Thereof | RPS14, RPL12, RPL13A | HSD11B1 174/4885CYP2D6 2066/4885KCNH2 970/4885 |
| US-20150353495-A1 | NICOTINAMIDES AS JAK KINASE MODULATORS | JAK2, JAK1, NADK | HSD11B1 2187/4885CYP2D6 1019/4885KCNH2 2615/4885 |
| US-20230131535-A1 | ARYLMETHYLENE AROMATIC COMPOUNDS AS Kv1.3 POTASSIUM SHAKER CHANNEL BLOCKERS | KCNJ2, KCNA3, KCNK3 | HSD11B1 1763/4885CYP2D6 670/4885KCNH2 7/4885 |
| US-20120108566-A1 | NICOTINAMIDES AS JAK KINASE MODULATORS | JAK2, JAK1, NADK | HSD11B1 2187/4885CYP2D6 1019/4885KCNH2 2615/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.